Anzeige
Mehr »
Freitag, 12.06.2026 - Börsentäglich über 12.000 News
Diese Aktie anschauen - Kurz vor Rallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
232 Leser
Artikel bewerten:
(1)

In Vitro Toxicology Testing Market worth $20.97 billion by 2031 | MarketsandMarkets

DELRAY BEACH, Fla., June 12, 2026 /PRNewswire/ -- According to MarketsandMarkets, the In Vitro Toxicology Testing Market is projected to grow from about USD 12.69 billion in 2026 to USD 20.97 billion by 2031, at a CAGR of 10.6%.

Browse 550 market data Tables and 50 Figures spread through 500 Pages and in-depth TOC on "In Vitro Toxicology Testing Market - Global Forecast to 2031"

In Vitro Toxicology Testing Market Size & Forecast:

  • Market Size Available for Years: 2025-2031
  • 2026 Market Size: USD 12.69 billion
  • 2031 Projected Market Size: USD 20.97 billion
  • CAGR (2026-2031): 10.6%

In Vitro Toxicology Testing Market Trends & Insights:

  • By type, the reagents & consumables segment dominated the in vitro toxicology products market, with a share of 27.8% in 2025.
  • By offering, the products segment accounted for a larger share than the services segment in 2025.
  • North America accounted for the largest market share of 39.3% in 2025.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209577065

The growth of the in vitro toxicology testing market is driven by the rising demand for non-animal testing methods, increasing regulatory focus on product safety, expanding pharmaceutical and biotechnology R&D, and growing adoption of predictive toxicity screening across chemicals, cosmetics, food, and medical device applications. Additionally, the market is supported by advancements in cell-based assays, 3D cell cultures, organ-on-chip platforms, high-throughput screening, and data analytics, which improve test relevance, speed, reproducibility, and scalability.

The consumables segment accounted for the largest share, by product & service, of the in vitro toxicology testing market in 2025.

By offering, the in vitro toxicology testing market has been categorized into products and services. Products are further segmented into reagent & consumables, assay kits, equipment and software. The products segment accounted for a larger share than the services segment in the in vitro toxicology testing market in 2025. The large share of this segment can be attributed to the increasing demand for high-quality reagents and the repeated use of media and reagents in in vitro toxicology studies. Additionally, the growing R&D activities in the pharmaceutical industry and the increased initiatives by governments in various countries to strengthen their product safety assessment capabilities are supporting the growth of this market.

Request Sample Pages@https://www.marketsandmarkets.com/requestsampleNew.asp?id=209577065

The organ toxicity testing segment is expected to grow at the highest rate during the forecast period.

By toxicity endpoint and test, the in vitro toxicology testing market has been segmented into organ toxicity testing, cytotoxicity testing, genotoxicity testing, dermal toxicity and skin irritation, corrosion, and sensitization, oxidative stress and mechanistic toxicity, and other toxicity endpoints and tests. In 2025, the organ toxicity testing segment led the product market, supported by strong use of hepatotoxicity, cardiotoxicity, ocular toxicity, and neurotoxicity assays in early safety screening. This can be attributed to increasing regulatory demands for safety assessment and reducing animal testing, continuous advancements in cell culture and tissue engineering technologies, and increasing drug development needs.

The pharmaceutical & biotechnology companies segment accounted for the largest share in the in vitro toxicology testing services market in 2025.

By end user, the in vitro toxicology testing services market has been segmented into pharmaceutical & biotechnology companies, consumer care companies, food & beverages companies, academic and research institutes, and other end users. In 2025, pharmaceutical & biotechnology companies accounted for the largest share of the services market, supported by extensive outsourcing of cytotoxicity, genotoxicity, hepatotoxicity, cardiotoxicity, ADME-Tox, and early safety screening studies to specialized CROs and testing laboratories. This dominance is driven by the high volume of drug discovery and preclinical development programs, rising biologics and advanced therapy pipelines, and the need to identify toxic liabilities early to reduce late-stage clinical failures and development costs.

The cell culture technologies segment accounted for the largest share in the in vitro toxicology testing products market in 2025.

By technology, the in vitro toxicology testing products market has been segmented into cell culture technologies, high-throughput and high-content technologies, omics technologies, organotypic and microphysiological-based technologies, and other technologies. In 2025, the cell culture technologies segment accounted for the largest share. This is mainly because most in vitro toxicology workflows depend on cell lines, primary cells, culture media, sera, buffers, reagents, assay plates, and 2D/3D culture models for cytotoxicity, hepatotoxicity, dermal, ocular, cardiotoxicity, and neurotoxicity testing. The segment's dominance is supported by the broad use of cell-based assays for early compound screening, safety profiling, and mechanism-of-toxicity assessment.

Europe accounted for the largest share of the in vitro toxicology testing market in 2025.

The in vitro toxicology testing market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa. North America dominated the market in 2025 due to the strong presence of pharmaceutical and biotechnology companies, advanced CRO infrastructure, high R&D spending, and early adoption of cell-based assays, high-throughput screening, organ toxicity models, and predictive toxicology platforms.

Inquire Before Buying@https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=209577065

Top Companies in In Vitro Toxicology Testing Market:

The Top Companies in In Vitro Toxicology Testing Market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), SGS SA (Switzerland), Bio-Rad Laboratories, Inc. (US), Evotec SE (Germany), Promega Corporation (US), Catalent, Inc. (US), Agilent Technologies, Inc. (US), Intertek Group plc (UK), Revvity (US), Inotiv (US), BioIVT (US), Lonza (Switzerland), Creative Biolabs (US), Shanghai Medicilon Inc. (China), Creative Bioarray (US), Aragen Life Sciences Ltd. (India), Enzo Biochem Inc. (US), Microbac Laboratories, Inc. (US), Vimta Labs Ltd. (India), Pacific BioLabs Inc. (US), and MB Research Laboratories (US).

Browse Adjacent Markets: Biotechnology Market Research Reports & Consulting

Related Reports:

Cell Based Assays Market - Global Forecast to 2030

High-Throughput Screening (HTS) Market - Global Forecast to 2031

Flow Cytometry Market - Global Forecast to 2033

In Vitro Diagnostics Market - Global Forecast to 2030

Cell Culture Market - Global Forecast to 2030

About MarketsandMarkets

MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/in-vitro-toxicology-testing-market-worth-20-97-billion-by-2031--marketsandmarkets-302798882.html

© 2026 PR Newswire
Software vor dem Comeback – diese 5 Aktien könnten durchstarten!
Während Halbleiter- und KI-Infrastrukturwerte von einem Hoch zum nächsten jagen, wurden viele Software-Aktien in den vergangenen Monaten regelrecht aus den Depots gedrängt. Die Angst vor Disruption hat Investoren zu einem radikalen Strategiewechsel veranlasst – mit der Folge, dass zahlreiche Qualitätsunternehmen heute auf Mehrjahrestiefs notieren.

Doch genau hier entsteht eine seltene Chance. Denn während die Bewertungen im Halbleitersektor inzwischen auf ambitionierten Niveaus liegen, ist der Bewertungsabschlag bei Software-Titeln so hoch wie seit Jahren nicht mehr. Gleichzeitig liefern viele Unternehmen weiterhin starke Wachstumszahlen und integrieren KI erfolgreich in ihre Geschäftsmodelle. Die Diskrepanz zwischen Kursentwicklung und operativer Stärke könnte sich schon bald auflösen.

Für Anleger bedeutet das: antizyklisch denken und gezielt zugreifen, bevor der Markt dreht. Denn erste technische Signale deuten darauf hin, dass sich die Trendwende bereits anbahnt.

In unserem aktuellen Spezialreport stellen wir fünf Software-Aktien vor, die besonders aussichtsreich positioniert sind – mit starker Marktstellung, attraktiver Bewertung und hohem Aufholpotenzial.

Jetzt den kostenlosen Report sichern – bevor der Software-Rebound Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.